Previous 10 | Next 10 |
Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) inks an agreement with Pfizer (NYSE: PFE ) for global rights to antisense drug AKCEA-ANGPTL3-Lrx for certain cardiovascular and metabolic diseases. More news on: Ionis Pharmaceuticals, Inc., Akcea Therapeu...
BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive licensing agreement...
Investing in growth stocks can feel like a roller-coaster ride. For instance, at the beginning of the year, Ionis Pharmaceuticals (NASDAQ: IONS) was trading at $52 a share. By April, the stock was up to $86 a share. And now it's back down to $59. That's a fair amount of volatility! Indi...
Monday was an up-and-down day on Wall Street, with indexes ultimately closing mixed. Gains in some major benchmarks were small as fears about a recession in Europe held stocks back early, but U.S. investors have higher hopes for the domestic economy to escape the same fate. Even so, some compani...
Gainers: Interlink Electronics ( OTCPK:LINK ) +37% . Avadel Pharmaceuticals plc (NASDAQ: AVDL ) +33% . Arotech Corporation (NASDAQ: ARTX ) +31% . Plus Therapeutics (NASDAQ: PSTV ) +25% . Cesca Therapeutics (NASDAQ: KOOL ) +20% . PriceSmart (NASDAQ: PSMT ) +18% . Dova Pharmaceuticals...
Autolus Therapeutics (NASDAQ: AUTL ) initiated with Buy rating and $26 (99% upside) price target at Needham. More news on: Autolus Therapeutics plc, Edwards Lifesciences Corporation, Elanco Animal Health Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...
Akcea Therapeutics' (NASDAQ: AKCA ) board of directors has appointed Damien McDevitt, Ph.D., as interim chief executive officer (CEO), effective immediately. More news on: Akcea Therapeutics, Inc., Healthcare stocks news, Read more ...
BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed Damien McDevitt, Ph.D., a member of its board of directors, as interim chief executive off...
Introduction Ionis ( IONS ) is a mid-cap ($9.3B) pharmaceuticals and a leader in RNA-targeted drug discovery and development. Its diverse pipeline comprises drug targets for neurological, cardiometabolic, renal, rare/orphan and oncological diseases. In line with its business model, ION...
Topline results from a Phase 1 clinical trial evaluating Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) AKCEA-TTR-Lrx in healthy volunteers showed a treatment effect. The data were presented at the Heart Failure Society of American Annual Scientific Me...
News, Short Squeeze, Breakout and More Instantly...
Akcea Therapeutics Inc. Company Name:
AKCA Stock Symbol:
NASDAQ Market:
Akcea Therapeutics Inc. Website:
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif. , Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, In...
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif. , Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...